The Use of Vasoactive Agents in Pulmonary Embolism Among the Critically Ill: A Multi-Centred, Retrospective Cohort Study in Queensland Intensive Care Units
Journal of Intensive Care Medicine · 2026
DOI: 10.1177/08850666251415168 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Intensive Care Medicine, 2026. Verfasst von Ashton Moh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Mater Health Services, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Pulmonary Embolism, Vasoconstrictor Agents, Critical Illness. Die Arbeit nennt 52 Literaturangaben.
Themen: Intensivpflege
Abstract (Originalsprache)
Background
Pulmonary embolism may cause hemodynamic instability requiring vasoactive support, but evidence on guiding agent selection is very limited.
Methods
A retrospective cohort study of adult admissions to 12 Intensive Care Units in Queensland, Australia between 2015–2021. Clinical and outcome data was obtained through statewide hospital databases.
Results
Of 89,123 admissions, 460 (0.6%) patients had a primary diagnosis of pulmonary embolism. Vasoactive infusions were administered within the first 24 h of ICU admission to 182/460 patients (39.6%) and 209/460 (45.4%) patients at any time during ICU admission. Norepinephrine was the most common (175/209; 83.7%), followed by epinephrine (37/209; 17.7%). The cohort had a median ICU length of stay of 3 days (IQR; 2-5), and a 30-day mortality rate of 11.3% (52/460). Higher vasoactive requirement on day-1 was associated with significantly higher 30-day mortality (odds ratio per 1-unit increase in vasoactive-inotrope score of 3.72, 95% confidence interval 1.80-8.75, P < .001).
Conclusion
Primary diagnosis of PE is uncommon among ICU presentations but 45% of patients require vasoactive support. Norepinephrine was the most used vasoactive agent. Higher vasoactive requirements reflected greater illness severity and were associated with higher 30-day mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mater Health Services, Brisbane, Queensland, Australia.
- School of Medicine, Queensland University of Technology, Brisbane, Queensland, Australia.
- Caboolture Hospital, Caboolture, Queensland, Australia.
- James Mayne Academy of Critical Care, University of Queensland, St Lucia, Queensland, Australia.
- The Prince Charles Hospital, Brisbane, Queensland, Australia.
- School of Nursing and Midwifery, Griffith University, Gold Coast, Queensland, Australia.
ORCID-Profile: Ashton Moh, Felicity Edwards, Prashanti Marella, Andrea Marshall, Alexis Tabah, Kyle White, Sebastiaan Blank, Stephen Whebell, Stephen Luke, Peter Garrett, Hayden White, Kevin Laupland, Antony Attokaran, Mahesh Ramanan
Zitieren
APA
Moh, A., Edwards, F., Marella, P., Lavana, J., Marshall, A., Tabah, A., White, K., Blank, S., Whebell, S., Luke, S., Garrett, P., White, H., Laupland, K., Attokaran, A., & Ramanan, M. (2026). The Use of Vasoactive Agents in Pulmonary Embolism Among the Critically Ill: A Multi-Centred, Retrospective Cohort Study in Queensland Intensive Care Units. Journal of Intensive Care Medicine. https://doi.org/10.1177/08850666251415168
Vancouver
Moh A, Edwards F, Marella P, Lavana J, Marshall A, Tabah A, et al. The Use of Vasoactive Agents in Pulmonary Embolism Among the Critically Ill: A Multi-Centred, Retrospective Cohort Study in Queensland Intensive Care Units. Journal of Intensive Care Medicine. 2026. doi:10.1177/08850666251415168
BibTeX
@article{Moh2026,
author = {Moh, Ashton and Edwards, Felicity and Marella, Prashanti and Lavana, Jayshree and Marshall, Andrea and Tabah, Alexis and White, Kyle and Blank, Sebastiaan and Whebell, Stephen and Luke, Stephen and Garrett, Peter and White, Hayden and Laupland, Kevin and Attokaran, Antony and Ramanan, Mahesh},
title = {The Use of Vasoactive Agents in Pulmonary Embolism Among the Critically Ill: A Multi-Centred, Retrospective Cohort Study in Queensland Intensive Care Units},
journal = {Journal of Intensive Care Medicine},
year = {2026},
doi = {10.1177/08850666251415168}
}
EUVIMED